SCM
AZN icon

Suvretta Capital Management’s AstraZeneca AZN Stock Holding History

Suvretta Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-75,000
Closed -$5.36M – 34
2014
Q3 		$5.36M Buy
+75,000
New +$5.49M 0.47% 35

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Suvretta Capital Management's AZN Position: Q1 2024 in Review

Suvretta Capital Management sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 35,245 shares — an estimated $4.75M sold.

Suvretta Capital Management first reported a position in AZN in Q4 2022 and held it in 5 quarters. The position peaked at $4.77M in Q3 2023. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

  • Suvretta Capital Management reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 35,245 AstraZeneca shares in Q1 2024, an estimated $4.75M.
  • Suvretta Capital Management first reported a position in AstraZeneca in Q4 2022 and held it in 5 quarters.
  • Suvretta Capital Management's AstraZeneca position peaked at $4.77M in Q3 2023.
  • 1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.